Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 9/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6353143 | 1.00 | GRIA4 (0.45) | GRIA4TRPA1CNR2CNR1GRIA2 | |
| SCHEMBL6357523 | 0.93 | GRIA4 (0.41) | GRIA4CNR2GRIA2 | |
| SCHEMBL6345852 | 0.93 | GRIA4 (0.41) | GRIA4CNR2GRIA2 | |
| SCHEMBL6345849 | 0.93 | GRIA4 (0.41) | GRIA4CNR2GRIA2 | |
| SCHEMBL6347705 | 0.90 | LMNA (0.41) | GRIA4CNR2SLC6A9OPRM1OPRL1 | |
| SCHEMBL6356541 | 0.90 | LMNA (0.41) | GRIA4CNR2SLC6A9OPRM1OPRL1 | |
| SCHEMBL6347708 | 0.90 | LMNA (0.41) | GRIA4CNR2SLC6A9OPRM1OPRL1 | |
| SCHEMBL6357698 | 0.89 | GRIA4 (0.42) | GRIA4GRIA2 | |
| SCHEMBL6345869 | 0.89 | GRIA4 (0.42) | GRIA4GRIA2 | |
| SCHEMBL6345867 | 0.89 | GRIA4 (0.42) | GRIA4GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900353-B2 | Cyclopentyl sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | CANTRELL BUDDY EUGENE (US) | 2004-04-08 | — | — | US | disclosed |
| EP-1334087-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002032858-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | GRIN2A, GRIN1, GRIK5 | GRIA4 15/4885TRPA1 355/4885CNR2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.